Navigation Links
Biovista and the CFIDS Association of America Achieve Drug Repositioning Milestone with Pre-IND Meeting
Date:5/29/2013

CHARLOTTESVILLE, Virginia and CHARLOTTE, North Carolina, May 29, 2013 /PRNewswire/ --

Biovista and the CFIDS Association of America announced today the successful completion of the first phase of their collaboration. Funded as part of the CFIDS' Research Institute Without Walls, Biovista identified candidate treatments for CFS using its state-of-the-art COSS approach. Two candidate treatments, including a combination therapy, were identified and are being prepared for proof-of-concept clinical trials, with an FDA pre-IND meeting scheduled in Q3 2013.

"We are very excited to have reached this stage within a year of starting our collaboration. We look forward to furthering our understanding of this complex disease and developing a treatment that will improve CFS patients' quality of life," said Dr. Andreas Persidis , Biovista's CEO. "Our work is an example of things to come in terms of novel collaboration models that promise to accelerate treatment development and, through the drug repositioning approach, do so cost effectively," Dr Persidis added.

"There is a big gap in the pipeline that moves basic laboratory research into safe and effective treatments. Without a bridge to bring discoveries to the clinic, laboratory research rarely becomes more than a paper. We are providing the means for basic researchers to move discoveries through the translational research pipeline with our Research Institute Without Walls," said Kim McCleary , president and CEO of CFIDS.

"Therapies for ME/CFS are an unmet medical need. This is largely due to the lack of translating the scientific knowledge into meaningful impact for patients," added Dr. Suzanne D. Vernon , Scientific Director of CFIDS. "We understand the ME/CFS knowledgebase and know how to fill this gap. Biovista recognized the opportunity for discovery. This drug repositioning project is an excellent example of effective use of existing information to make a new treatment discovery."

About Biovista

Biovista finds novel uses for existing drugs and profiles their side effects using mechanism of action analysis. Biovista develops its own pipeline in CNS, oncology, auto-immune and rare diseases and collaborates with biopharmaceutical companies and Patient Groups on indication expansion, portfolio de-risking, and adverse event prediction. (http://www.biovista.com).

About CFIDS

The CFIDS Association of America is at the leading edge of ME/CFS research. For more information, please visit The Association's web site at http://www.cfids.org or their research blog at http://www.Research1st.org

Contacts
Biovista
Dr. Andreas Persidis
andreasp@biovista.com
T: +1-434-242-6514
 
The CFIDS Association of America
Dr. Suzanne D. Vernon
sdvernon@cfids.org


'/>"/>
SOURCE Biovista
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
3. Washington State Medical Association (WSMA) Urges Adults to Get Recommended Immunizations
4. Shire to Present Scientific Data Across Range of Psychiatric Disorders at American Psychiatric Association Annual Meeting May 5-9
5. Data Presented at the American Psychiatric Association Annual Meeting Supports Gender-Specific Dosing of Intermezzo® (zolpidem tartrate) Sublingual Tablets CIV
6. Percutaneous Tibial Nerve Stimulation Included in the American Urological Associations Overactive Bladder Clinical Treatment Guidelines
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
9. Attack on the Website of the American Pharmacists Association
10. China Botanic Sponsors Wild Plant Protection Association of China Meeting; Expects to Lead the Siberian Ginseng Conservation Association
11. CyberKnife® Prostate SBRT Outcomes and Quality of Life Data Presented at American Urological Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. ... appointed Paul M. Bisaro as Impax,s President ... Company,s Board, effective March 27, 2017. Mr. Bisaro will ... as Interim President and Chief Executive Officer since December ... generic and branded pharmaceutical experience, Mr. Bisaro, 56, is ...
(Date:3/27/2017)... 2017 Invivotek, LLC, a Genesis Biotechnology Group ... pharmacology contract research organization (CRO), announced the completion ... expanded preclinical research facility in Hamilton, New ... renewable energy source to reduce costs and lessen the ... Genesis Solar Farm follows Invivotek,s recent expansion from a ...
(Date:3/24/2017)... , March 24, 2017  Zymo Research ... and Hamilton Robotics, Inc., who designs, manufactures ... ongoing collaboration that teams Zymo Research,s DNA ... and DNA extraction products with Hamilton,s high-throughput ... optimized methods for microbiomics and RNA isolation ...
Breaking Medicine Technology:
(Date:3/27/2017)... ... March 27, 2017 , ... From 1999 to 2015, ... for over 33,000 of the 52,404 drug-related deaths in 2015.(2) To combat the ... proposes a tax on prescription opioids to fund drug rehabilitation and prevention services.(3) ...
(Date:3/26/2017)... ... March 26, 2017 , ... ... receive the RealSelf 100 Award, a prestigious award honoring the top influencers on ... to find and connect with doctors and clinics. , In 2016, more than ...
(Date:3/24/2017)... ... March 24, 2017 , ... Clean Earth, Inc., ... and hazardous and non-hazardous materials announced today the acquisition of privately owned ... add four additional processing facilities and a vast array of additional technologies, services, ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease affects billions of ... United States, it’s a threat that is constantly changing and evolving. Mediaplanet's “Fighting ... offers strategies for the healthcare community to help decrease the number of completely ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA Senior ... not obey the rules Congress has directed the CBO to follow. The CBO itself ... would restore. Yet, it estimates a reduction in employer-based coverage due to the GOP ...
Breaking Medicine News(10 mins):